19:56 , Mar 14, 2017 |  BC Week In Review  |  Clinical News

PKX-001: Ph I started

ProtoKinetix began an open-label, Canadian Phase I trial to evaluate transplanted islet cells treated with PKX-001 in up to 10 patients. ProtoKinetix Inc. (OTCQB:PKTX), St. Marys, W.Va.  Product: PKX-001 (AAGP)  Business: Endocrine/Metabolic  Molecular target: NA  Description: Anti-aging glycopeptide (AAGP), a...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

ProtKinetix preclinical data

In rats, 0.2% topical AAGP penetrated the protective barriers of the eye and was detected within the cornea and ciliary body. There were no side effects associated with administration of the anti-inflammatory synthetic anti-aging glycopeptide...